Therapy Areas: Autoimmune
Rigel Pharmaceuticals Inc wins US FDA approval for TAVALISSE for treating chronic immune thrombocytopenia in adult patients
18 April 2018 - Biotechnology company Rigel Pharmaceuticals Inc (Nasdaq:RIGL) revealed on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for TAVALISSE for the treatment...
Mylan acquires exclusive license to commercialise biosimilar to Humira
13 April 2018 - United States-based Mylan has acquired an exclusive license to commercialise a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe, it was reporte...
Magenta Therapeutics Raises USD 52m in Series C Financing
11 April 2018 - - Cambridge, Massachusetts-based biotechnology company Magenta Therapeutics Inc. has completed a USD 52m Series C financing, the company said.
Proceeds from the financing will be...
Be The Match BioTherapies Makes Second Equity Investment in Magenta Therapeutics
11 April 2018 - - Minneapolis, Minnesota-based cellular therapies developers partner Be The Match BioTherapies has made its second equity investment in Cambridge, Massachusetts-based biotechnology com...
Protalex Expands Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia to UK
11 April 2018 - - Florham Park, New Jersey-based clinical-stage biopharmaceutical company Protalex, Inc. (OTCQB: PRTX) has enrolled the first of three patients in cohort four of its US/UK Phase 1/2 tr...
SMC approves four new therapies for NHS Scotland
10 April 2018 - The Scottish Medicines Consortium (SMC) has approved funding for four new therapies to be made available via NHS Scotland, Pharma Times reported on Tuesday.Shire's (LON: SHP) Reve...